Back to All NewsJeuveau Stays on U.S. Market After Court Order
Posted By American Med Spa Association, Wednesday, February 17, 2021
Share
Evolus Inc. rose after its rival to the Botox wrinkle treatment was allowed to remain for sale in the U.S. temporarily while an appeals court considers staying an import ban won by AbbVie Inc.’s Allergan that was to go into effect Tuesday.
Daewoong Pharmaceutical Co. and Evolus filed the request early Saturday, urging the U.S. Court of Appeals for the Federal Circuit to put on hold on the ban against their treatment, Jeuveau. Allergan and its South Korean partner, MedyTox Inc., in December won a ruling that Jeuveau is made using MedyTox’s secret process to turn the deadly botulinum toxin into a cosmetic product.
The import ban is “temporarily stayed and the government is directed not to enforce the remedial orders until further notice while the court considers the motion for a stay pending appeal,” the Federal Circuit said in an order posted on its electronic docket. The court ordered additional legal arguments could be submitted through March 5.
Read more at Bloomberg >>
Daewoong Pharmaceutical Co. and Evolus filed the request early Saturday, urging the U.S. Court of Appeals for the Federal Circuit to put on hold on the ban against their treatment, Jeuveau. Allergan and its South Korean partner, MedyTox Inc., in December won a ruling that Jeuveau is made using MedyTox’s secret process to turn the deadly botulinum toxin into a cosmetic product.
The import ban is “temporarily stayed and the government is directed not to enforce the remedial orders until further notice while the court considers the motion for a stay pending appeal,” the Federal Circuit said in an order posted on its electronic docket. The court ordered additional legal arguments could be submitted through March 5.
Read more at Bloomberg >>
